Short answer
Kura Oncology, Inc. (KURA) filed an 8-K current report with the SEC on September 9, 2026 reporting Item 8.01 (Other Events). Caspian raised $50.0M in Series A financing, funding cardiometabolic development outside Kura’s core oncology focus.
Kura Oncology, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Caspian raised $50.0M in Series A financing, funding cardiometabolic development outside Kura’s core oncology focus
- Kura invested $4.3M and retains approximately 49.2% ownership, preserving substantial economic exposure without majority control
- Kura contributed KO-7246 and related assets, receiving Caspian common stock plus reimbursement of up to $1.5M
- Caspian assumes development, regulatory, and commercialization responsibility for menin inhibitors in diabetes and cardiometabolic diseases
- Kura will provide research, administrative, and other services under renewable one-year terms, creating potential ongoing service-fee revenue
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Kura Oncology, Inc. 8-K filings
Get the next KURA 8-K as it lands
Follow KURA for push alerts, or ask the research agent what this filing means.